Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...
AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...
Zacks.com on MSN5d
AbbVie Inks a Deal With Neomorph for Molecular Glue DegradersPer the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and ...
We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...
J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects. "As a leader in hematologic malignancies, AbbVie is ...
Insider Monkey on MSN11d
Why Is AbbVie Inc. (ABBV) Among Louis Navellier’s Top Long-term Stock Picks?Louis Navellier is a prominent American investor, author, and financial analyst, best known for his quantitative approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback